ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gets upgraded to Outperform by Svb Leerink with a price target of $50.00

Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Story continues below

Today, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock received an upgrade by Svb Leerink from Market Perform to Outperform with a price target of $50.00.

There are 10 Buy Ratings, 2 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy with a consensus target price of $45.1538 per share, a potential 12.77% upside.

Some recent analyst ratings include

  • 9/13/2019-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gets upgraded to Outperform by Svb Leerink with a price target of $50.00
  • 9/13/2019-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gets upgraded to Outperform by Leerink Swann
  • 9/10/2019-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had its Buy rating reiterated by JPMorgan Chase & Co.
  • 9/10/2019-ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gets upgraded to Buy by Canaccord Genuity with a price target of $50.00
  • On 9/11/2019 Eric Alejandro Miller, Insider, sold 4,645 with an average share price of $41.18 per share and the total transaction amounting to $191,281.10.
  • On 9/9/2019 Eric Alejandro Miller, Insider, sold 28,467 with an average share price of $39.49 per share and the total transaction amounting to $1,124,161.83.
  • On 9/9/2019 James M Daly, Director, sold 30,000 with an average share price of $37.80 per share and the total transaction amounting to $1,134,000.00.
  • On 1/9/2019 Laura Brege, Director, sold 10,000 with an average share price of $20.00 per share and the total transaction amounting to $200,000.00.
  • On 11/30/2018 Bros. Advisors Lp Baker, Director, bought 11,764,705 with an average share price of $17.00 per share and the total transaction amounting to $199,999,985.00.
  • On 9/20/2018 Bros. Advisors Lp Baker, Director, bought 1,210,776 with an average share price of $18.70 per share and the total transaction amounting to $22,641,511.20.
  • On 3/1/2018 Daniel B Soland, Director, bought 7,000 with an average share price of $23.91 per share and the total transaction amounting to $167,370.00.

Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 39.98 up +0.84 2.15% with 40.12 shares trading hands.

An ad to help with our costs